title: Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma.
abstract: We have evaluated whether allogeneic hematopoietic stem cell transplantation (HSCT) could induce an antitumor effect in patients with metastatic solid tumors. A total of 12 HLA-identical siblings and 6 HLA-A-, -B- and -DR beta 1-compatible unrelated grafts were used. Diagnoses were adenocarcinoma of kidney (n=10), colon (n=6), breast (n=1) and cholangiocarcinoma (n=1). Conditioning was fludarabine 30 mg/m(2)/day for 3 days and 2 Gy of total body irradiation. Recipients of unrelated HSCT were also given thymoglobuline and two additional days of fludarabine. The median CD34+ cell dose was 7.5 x 10(6)/kg. Immunosuppression was mycophenolate mofetil and cyclosporin. Among all, 12 patients became complete donor chimeras within a median of 28, 29 and 65 days for B, myeloid and T cells, respectively. Two patients rejected the grafts, one developed marrow aplasia and three were mixed chimeras. The probability of grades II-IV acute graft-versus-host-disease (GVHD) was 57%. Regression of all tumor metastases was seen in one patient with colon carcinoma. Another patient with colon and two with renal carcinoma had regression of lung metastases, but progression of metastases in the liver and/or bone. Necrosis of lung metastasis was found in one further patient with renal carcinoma who died of graft-versus-host-disease (GVHD). In all, 10 patients died; four of transplant-related complications, one of trauma and five of progressive disease. Thus, progression was common after allogeneic HSCT in unselected patients with advanced solid tumors. However, the regression of some metastases associated with GVHD provides suggestive evidence that the GVHD effect may occur in renal and colon adenocarcinoma using reduced intensity conditioning.
authors.affiliation: Center for Allogenic Stem Cell Transplantation and Division of Immunology, Microbiology and Pathology, Huddinge University Hospital, Stockholm, Sweden.
authors.forename: P
authors.initials: P
authors.lastname: Hentschke
authors.forename: L
authors.initials: L
authors.lastname: Barkholt
authors.forename: M
authors.initials: M
authors.lastname: Uzunel
authors.forename: J
authors.initials: J
authors.lastname: Mattsson
authors.forename: P
authors.initials: P
authors.lastname: Wersäll
authors.forename: P
authors.initials: P
authors.lastname: Pisa
authors.forename: J
authors.initials: J
authors.lastname: Martola
authors.forename: N
authors.initials: N
authors.lastname: Albiin
authors.forename: A
authors.initials: A
authors.lastname: Wernerson
authors.forename: M
authors.initials: M
authors.lastname: Söderberg
authors.forename: M
authors.initials: M
authors.lastname: Remberger
authors.forename: A
authors.initials: A
authors.lastname: Thörne
authors.forename: O
authors.initials: O
authors.lastname: Ringdén
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000628:therapy; D000368:Aged; D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy; D018281:Cholangiocarcinoma / Q000401:mortality / Q000473:pathology / Q000628:therapy; D003110:Colonic Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007680:Kidney Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D033581:Stem Cell Transplantation / Q000379:methods*; D016019:Survival Analysis; D013997:Time Factors; D019172:Transplantation Conditioning / Q000379:methods*; D016896:Treatment Outcome; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014916:Whole-Body Irradiation
chemical_list: D014740:Vidarabine; C024352:fludarabine